First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide
This clinical trial studies the side effects of 18F-alphavbeta6-binding-peptide and how well it works in imaging patients with primary or cancer that has spread to the breast, colorectal, lung, or pancreatic. Radiotracers, such as 18F-alphavbeta6-binding-peptide, may improve the ability to locate cancer in the body.
Checked against the public recordLast updated Feb 27, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Early Phase 1
- Sponsor
- Julie L. Sutcliffe, Ph.D
- Interventions being studied
- Drug: 18F-αvβ6-BP
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Diagnosed with primary or metastatic cancer in one or more of the following locations: breast, colorectal, lung, pancreas * Eastern Cooperative Oncology Group (ECOG) performance score of 0-1 * Will sign the Institutional Review Board (IRB)-approved consent form * Able to remain motionless for up to 30-60 minutes per scan Exclusion Criteria: * Creatinine \> 2 x upper limit of normal * Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) \> 2 x upper limit of normal * Life expectancy \< 3 months (mo) * Women who are pregnant or breast-feeding * Patients who cannot undergo PET/compute tomography (CT) scanning * Lack of availability for follow-up assessments * Participation in another clinical trial involving an investigational agent within 4 weeks of enrollment
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of California Davis Comprehensive Cancer CenterSacramento, California
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 27, 2026. Always confirm current availability with the study team.